TANAF
Tian'an Technology Group Ltd., through its subsidiaries, engages in the research, development, and production of graphene products for the health therapy industry in China. The company offers graphene far infrared energy rooms, pure graphene heating music blankets, graphene pillows, pure graphene heating knee compartments, pure graphene heating knee pads, suspension moxibustion instrument, and pu… Read more
TANAF (TANAF) - Net Assets
Latest net assets as of June 2025: $40.46K USD
Based on the latest financial reports, TANAF (TANAF) has net assets worth $40.46K USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($766.79K) and total liabilities ($726.33K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $40.46K |
| % of Total Assets | 5.28% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
TANAF - Net Assets Trend (2021–2024)
This chart illustrates how TANAF's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for TANAF (2021–2024)
The table below shows the annual net assets of TANAF from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $20.03K | +103.68% |
| 2023-12-31 | $-543.96K | -76.90% |
| 2022-12-31 | $-307.50K | +46.20% |
| 2021-12-31 | $-571.53K | -- |
Equity Component Analysis
This analysis shows how different components contribute to TANAF's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7593600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $629.79K | 3144.53% |
| Total Equity | $20.03K | 100.00% |
TANAF Competitors by Market Cap
The table below lists competitors of TANAF ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ROBERT WALTERS PLC LS-20
F:RBW
|
$61.53 Million |
|
Stealth Group Holdings Ltd
AU:SGI
|
$61.54 Million |
|
ABL GROUP ASA NA NK-10
F:26Q
|
$61.55 Million |
|
Cristales
SN:CRISTALES
|
$61.55 Million |
|
SCG Decor PCL
BK:SCGD
|
$61.51 Million |
|
Blueharbor Bank
OTCQX:BLHK
|
$61.50 Million |
|
Auxly Cannabis Group Inc
OTCQX:CBWTF
|
$61.49 Million |
|
Scandinavian Astor Group AB
ST:ASTOR
|
$61.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TANAF's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -543,964 to 20,028, a change of 563,992.
- Net income of 454,590 contributed positively to equity growth.
- Other factors increased equity by 109,402.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $454.59K | +2269.77% |
| Other Changes | $109.40K | +546.25% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares TANAF's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 25340.81x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $-0.01 | $11.15 | x |
| 2022-12-31 | $-0.01 | $11.15 | x |
| 2023-12-31 | $-0.01 | $11.15 | x |
| 2024-12-31 | $0.00 | $11.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TANAF utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2269.77%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 25.49%
- • Asset Turnover: 1.74x
- • Equity Multiplier: 51.21x
- Recent ROE (2269.77%) is above the historical average (567.44%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -321.75% | 0.47x | 0.00x | $-62.10K |
| 2022 | 0.00% | -143.32% | 2.62x | 0.00x | $-249.77K |
| 2023 | 0.00% | -101.37% | 1.39x | 0.00x | $-195.61K |
| 2024 | 2269.77% | 25.49% | 1.74x | 51.21x | $452.59K |
Industry Comparison
This section compares TANAF's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TANAF (TANAF) | $40.46K | 0.00% | 17.95x | $61.53 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |